An image of rising and declining prices
Markets

Neogen Earns Membership In 95-Plus Composite Rating Club

An image of rising and declining prices
Shutterstock photo

Neogen ( NEOG ) saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 94 the day before.

[ibd-display-video id=449435 width=50 float=left autostart=true] The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they begin to launch a significant move.

Neogen has now climbed above a proper buy zone after clearing the 70.07 entry in a flat base.

Looking For Winning Stocks? Try This Simple Routine

The stock sports a 92 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 92% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

The company posted a 19% EPS gain for Q1. Sales growth increased 14%, up from 10% in the prior quarter. That marks one quarter of increasing revenue increases.

Neogen earns the No. 10 rank among its peers in the Medical-Products industry group. Abiomed ( ABMD ), Align Technology ( ALGN ) and Lemaitre Vascular ( LMAT ) are among the top 5 highly-rated stocks within the group.

RELATED:

Which Companies Are Now Outperforming 95% Of All Stocks?

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD NEOG ALGN LMAT

Other Topics

Stocks